Bambauer R, Schiel R. Therapeutic Apheresis and Immunosuppression in Immunologic Diseases: A Review and OwnObservations. Clin Immunol Res. 2021; 5(2): 1-36. ISSN 2639-8486
“TA should be reserved for treatment of children and adolescents
who are severely affected by PANDAS. In such patients, it
appears to be safe, well-tolerated, and beneficial treatment
option [130]. Bien et al reported in 2020, besides the first-line
interventions of steroids, IVIG, and TA as second-line treatments
cyclophosphamide or rituximab [131].”
Gabriella True
